Elicio Therapeutics, Inc. Share-based Payment Arrangement, Decrease for Tax Withholding Obligation
Elicio Therapeutics, Inc. (ELTX) reported Share-based Payment Arrangement, Decrease for Tax Withholding Obligation of $150.00 thousand for the 12-month period ending 2023-12-31, per its 10-K filed 2025-03-31.
Financial Statements › Notes › Equity › Stockholders' Equity Note
us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation · last filed 2025-03-31
- Elicio Therapeutics, Inc. share-based payment arrangement, decrease for tax withholding obligation for the quarter ending 2023-06-30 was $150.00K.
- Elicio Therapeutics, Inc. share-based payment arrangement, decrease for tax withholding obligation for the quarter ending 2021-12-31 was $0.00.
- Elicio Therapeutics, Inc. share-based payment arrangement, decrease for tax withholding obligation for the quarter ending 2021-09-30 was $94.00K.
- Elicio Therapeutics, Inc. share-based payment arrangement, decrease for tax withholding obligation for the quarter ending 2021-06-30 was $1.22M.
- Elicio Therapeutics, Inc. share-based payment arrangement, decrease for tax withholding obligation for fiscal 2023 was $150.00K.
- Elicio Therapeutics, Inc. share-based payment arrangement, decrease for tax withholding obligation for fiscal 2021 was $2.46M, a 6727.78% increase from fiscal 2020.
- Elicio Therapeutics, Inc. share-based payment arrangement, decrease for tax withholding obligation for fiscal 2020 was $36.00K.
| Period end | Share-based Payment Arrangement, Decrease for Tax Withholding Obligation 3 month | Share-based Payment Arrangement, Decrease for Tax Withholding Obligation 6 month | Share-based Payment Arrangement, Decrease for Tax Withholding Obligation 9 month | Share-based Payment Arrangement, Decrease for Tax Withholding Obligation 12 month |
|---|---|---|---|---|
| 2023-12-31 | $150.00K 10-K · filed 2025-03-31 | |||
| 2023-06-30 | $150.00K 10-Q · filed 2024-11-13 | |||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-17 | $94.00K derived: sum of 2 quarters · filed 2023-03-17 | $1.31M derived: sum of 3 quarters · filed 2023-03-17 | $2.46M 10-K · filed 2023-03-17 |
| 2021-09-30 | $94.00K 10-Q · filed 2022-11-14 | $1.31M derived: sum of 2 quarters · filed 2022-11-14 | $2.46M 10-Q · filed 2021-11-12 | |
| 2021-06-30 | $1.22M 10-Q · filed 2021-08-12 | $2.36M derived: sum of 2 quarters · filed 2022-11-14 | ||
| 2021-03-31 | $1.15M 10-Q · filed 2022-11-14 | |||
| 2020-12-31 | $36.00K 10-K · filed 2022-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |